rs6561424

Variant names:

• chr13-47988873-G-A
• rs6561424
• NM_003850.3:c.371+9C>T

Variant summary

Our verdict is Benign. Variant got -20 ACMG points: 0P and 20B. BP4_Strong BP6_Very_Strong BA1

The NM_003850.3(SUCLA2):​c.371+9C>T variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.787 in 1,610,790 control chromosomes in the GnomAD database, including 503,879 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★).

• Frequency:
  • Genomes: 𝑓 0.73 (41387 hom., cov: 33)
  • Exomes 𝑓: 0.79 (462492 hom.)
• Consequence: SUCLA2 NM_003850.3 intron
• Clinical Significance: Benign criteria provided, multiple submitters, no conflicts B:11
• Conservation: PhyloP100: 0.800

Genes affected

SUCLA2 (HGNC:11448): (succinate-CoA ligase ADP-forming subunit beta) Succinyl-CoA synthetase (SCS) is a mitochondrial matrix enzyme that acts as a heterodimer, being composed of an invariant alpha subunit and a substrate-specific beta subunit. The protein encoded by this gene is an ATP-specific SCS beta subunit that dimerizes with the SCS alpha subunit to form SCS-A, an essential component of the tricarboxylic acid cycle. SCS-A hydrolyzes ATP to convert succinate to succinyl-CoA. Defects in this gene are a cause of myopathic mitochondrial DNA depletion syndrome. A pseudogene of this gene has been found on chromosome 6. [provided by RefSeq, Jul 2008]

ACMG classification

Verdict is Benign. Variant got -20 ACMG points.

• BP4: Computational evidence support a benign effect (BayesDel_noAF=-0.84).
• BP6: Variant 13-47988873-G-A is Benign according to our data. Variant chr13-47988873-G-A is described in ClinVar as [Benign]. Clinvar id is 139358.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr13-47988873-G-A is described in Lovd as [Benign].
• BA1: GnomAd4 highest subpopulation (NFE) allele frequency at 95% confidence interval = 0.809 is higher than 0.05.

Transcripts

RefSeq

Gene	Transcript	HGVSc	HGVSp	Effect	Exon rank	MANE	Protein	UniProt
SUCLA2	NM_003850.3	c.371+9C>T		intron_variant	Intron 3 of 10	ENST00000646932.1	NP_003841.1

Ensembl

Gene	Transcript	HGVSc	HGVSp	Effect	Exon rank	TSL	MANE	Protein	Appris	UniProt
SUCLA2	ENST00000646932.1	c.371+9C>T		intron_variant	Intron 3 of 10		NM_003850.3	ENSP00000494360.1

Frequencies

GnomAD3 genomes AF: 0.730 AC: 110878 AN: 151976 Hom.: 41382 Cov.: 33

Gnomad AFR AF: 0.584

Gnomad AMI AF: 0.919

Gnomad AMR AF: 0.676

Gnomad ASJ AF: 0.796

Gnomad EAS AF: 0.798

Gnomad SAS AF: 0.623

Gnomad FIN AF: 0.797

Gnomad MID AF: 0.750

Gnomad NFE AF: 0.815

Gnomad OTH AF: 0.761

GnomAD3 exomes AF: 0.748 AC: 187378 AN: 250556 Hom.: 71245 AF XY: 0.750 AC XY: 101688 AN XY: 135602

Gnomad AFR exome AF: 0.581

Gnomad AMR exome AF: 0.635

Gnomad ASJ exome AF: 0.780

Gnomad EAS exome AF: 0.792

Gnomad SAS exome AF: 0.633

Gnomad FIN exome AF: 0.792

Gnomad NFE exome AF: 0.818

Gnomad OTH exome AF: 0.761

GnomAD4 exome AF: 0.793 AC: 1157108 AN: 1458696 Hom.: 462492 Cov.: 37 AF XY: 0.789 AC XY: 572835 AN XY: 725764

Gnomad4 AFR exome AF: 0.571

Gnomad4 AMR exome AF: 0.638

Gnomad4 ASJ exome AF: 0.783

Gnomad4 EAS exome AF: 0.780

Gnomad4 SAS exome AF: 0.636

Gnomad4 FIN exome AF: 0.791

Gnomad4 NFE exome AF: 0.820

Gnomad4 OTH exome AF: 0.784

GnomAD4 genome AF: 0.729 AC: 110913 AN: 152094 Hom.: 41387 Cov.: 33 AF XY: 0.728 AC XY: 54104 AN XY: 74366

Gnomad4 AFR AF: 0.583

Gnomad4 AMR AF: 0.675

Gnomad4 ASJ AF: 0.796

Gnomad4 EAS AF: 0.797

Gnomad4 SAS AF: 0.623

Gnomad4 FIN AF: 0.797

Gnomad4 NFE AF: 0.815

Gnomad4 OTH AF: 0.761

Alfa AF: 0.781 Hom.: 23772

Bravo AF: 0.715

Asia WGS AF: 0.689 AC: 2392 AN: 3476

EpiCase AF: 0.809

EpiControl AF: 0.806

ClinVar

Significance: Benign

Submissions summary: Benign:11

Revision: criteria provided, multiple submitters, no conflicts

Submissions by phenotype

not specified Benign:5

May 21, 2015

Eurofins Ntd Llc (ga)

Significance: Benign

Review Status: criteria provided, single submitter

Collection Method: clinical testing

- -

-

PreventionGenetics, part of Exact Sciences

Significance: Benign

Review Status: criteria provided, single submitter

Collection Method: clinical testing

- -

-

Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+

Significance: Benign

Review Status: no assertion criteria provided

Collection Method: clinical testing

- -

-

Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen

Significance: Benign

Review Status: no assertion criteria provided

Collection Method: clinical testing

- -

Jun 30, 2011

GeneDx

Significance: Benign

Review Status: criteria provided, single submitter

Collection Method: clinical testing

This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. -

not provided Benign:3

Feb 19, 2016

Mayo Clinic Laboratories, Mayo Clinic

Significance: Benign

Review Status: no assertion criteria provided

Collection Method: clinical testing

- -

-

Breakthrough Genomics, Breakthrough Genomics

Significance: Benign

Review Status: criteria provided, single submitter

Collection Method: not provided

- -

Apr 20, 2017

Athena Diagnostics

Significance: Benign

Review Status: criteria provided, single submitter

Collection Method: clinical testing

- -

Mitochondrial DNA depletion syndrome, encephalomyopathic form with methylmalonic aciduria Benign:3

Jan 12, 2018

Illumina Laboratory Services, Illumina

Significance: Benign

Review Status: criteria provided, single submitter

Collection Method: clinical testing

This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as benign is not then subjected to further curation. The score for this variant resulted in a classification of benign for this disease. -

Feb 03, 2025

Labcorp Genetics (formerly Invitae), Labcorp

Significance: Benign

Review Status: criteria provided, single submitter

Collection Method: clinical testing

- -

Jul 15, 2021

Genome-Nilou Lab

Significance: Benign

Review Status: criteria provided, single submitter

Collection Method: clinical testing

- -

Computational scores

Source: dbNSFP v4.3

Name	Calibrated prediction	Score	Prediction
BayesDel_noAF	Benign	-0.84
CADD	Benign	1.9
DANN	Benign	0.64
RBP_binding_hub_radar		0.0
RBP_regulation_power_radar		1.1

Splicing

Name	Calibrated prediction	Score	Prediction
SpliceAI score (max)		0.0		Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Other links and lift over

dbSNP: rs6561424; hg19: chr13-48563008;